GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » E10

Zevra Therapeutics (FRA:1GDA) E10 : €-30.12 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Zevra Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.368. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-30.12 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-04), Zevra Therapeutics's current stock price is €4.18. Zevra Therapeutics's E10 for the quarter that ended in Mar. 2024 was €-30.12. Zevra Therapeutics's Shiller PE Ratio of today is .


Zevra Therapeutics E10 Historical Data

The historical data trend for Zevra Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics E10 Chart

Zevra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -26.09

Zevra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -31.47 -26.09 -30.12

Competitive Comparison of Zevra Therapeutics's E10

For the Biotechnology subindustry, Zevra Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zevra Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's Shiller PE Ratio falls into.



Zevra Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zevra Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.368/131.7762*131.7762
=-0.368

Current CPI (Mar. 2024) = 131.7762.

Zevra Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -5.377 100.560 -7.046
201409 -11.327 100.428 -14.863
201412 -12.483 99.070 -16.604
201503 -7.176 99.621 -9.492
201506 -34.927 100.684 -45.713
201509 -9.694 100.392 -12.725
201512 -9.400 99.792 -12.413
201603 -2.874 100.470 -3.770
201606 8.259 101.688 10.703
201609 -13.116 101.861 -16.968
201612 -10.314 101.863 -13.343
201703 -16.606 102.862 -21.274
201706 -6.266 103.349 -7.990
201709 -9.128 104.136 -11.551
201712 -9.734 104.011 -12.332
201803 -22.968 105.290 -28.746
201806 -12.463 106.317 -15.447
201809 -12.889 106.507 -15.947
201812 2.532 105.998 3.148
201903 -6.514 107.251 -8.004
201906 -4.673 108.070 -5.698
201909 0.872 108.329 1.061
201912 -2.547 108.420 -3.096
202003 -1.738 108.902 -2.103
202006 0.186 108.767 0.225
202009 -0.577 109.815 -0.692
202012 -0.929 109.897 -1.114
202103 -2.092 111.754 -2.467
202106 -0.332 114.631 -0.382
202109 -0.043 115.734 -0.049
202112 0.044 117.630 0.049
202203 -0.045 121.301 -0.049
202206 -0.662 125.017 -0.698
202209 -0.192 125.227 -0.202
202212 0.151 125.222 0.159
202303 -0.355 127.348 -0.367
202306 -0.138 128.729 -0.141
202309 -0.375 129.860 -0.381
202312 -0.367 129.419 -0.374
202403 -0.368 131.776 -0.368

Add all the adjusted EPS together and divide 10 will get our e10.


Zevra Therapeutics  (FRA:1GDA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Zevra Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Zevra Therapeutics (FRA:1GDA) Business Description

Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines